Cefotetan

Bacteria, surgical prophylaxis therapy, Urinary tract infection + 9 more
Treatment
20 FDA approvals
7 Active Studies for Cefotetan

What is Cefotetan

CefotetanThe Generic name of this drug
Treatment SummaryCefotetan is an antibiotic used to treat bacterial infections. It is given as an injection into a vein or muscle and is effective against a wide range of bacteria, including both gram-positive and gram-negative. It is also very resistant to certain enzymes that can make antibiotics less effective.
Cefotanis the brand name
image of different drug pills on a surface
Cefotetan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cefotan
Cefotetan
1985
16

Approved as Treatment by the FDA

Cefotetan, also known as Cefotan, is approved by the FDA for 20 uses which include Osteomyelitis and Communicable Diseases .
Osteomyelitis
Communicable Diseases
Lower respiratory tract infection bacterial
Bone and Joint Infections
Pelvic Inflammatory Disease
Neisseria Gonorrhoeae Infection
Abdominal Infection
Bacterial Infections
Septicemia
Used to treat Sepsis in combination with null
Gynaecological infection
Bacterial Urinary Tract Infections
Bacteria
Intraabdominal Infections
surgical prophylaxis therapy
Urinary Tract Infection (UTI)
Postoperative Infections
Urinary tract infection
prophylaxis of Postoperative Infections
Antibiotics
Gonorrhea

Effectiveness

How Cefotetan Affects PatientsCefotetan is a strong antibiotic that can be given through a vein or muscle. It works against a lot of different types of bacteria, both good and bad, and is able to protect against certain types of antibiotics.
How Cefotetan works in the bodyCefotetan kills bacteria by stopping them from forming cell walls. It does this by blocking proteins that help in the formation of cell walls.

When to interrupt dosage

The prescribed dose of Cefotetan is subject to the determined affliction, which includes Antibiotics, Bacteria and Communicable Diseases. The measure of dosage is contingent upon the mode of administration (e.g. Intramuscular; Intravenous or Injection) noted in the following table.
Condition
Dosage
Administration
Communicable Diseases
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
prophylaxis of Postoperative Infections
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
surgical prophylaxis therapy
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Pelvic Inflammatory Disease
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Urinary Tract Infection (UTI)
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Gonorrhea
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Osteomyelitis
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Intraabdominal Infections
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Urinary tract infection
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Bacteria
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Antibiotics
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous
Postoperative Infections
100.0 mg/mL, , 200.0 mg/mL, 10000.0 mg, 2000.0 mg, 1000.0 mg, 1000.0 mg/mL, 2000.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution - Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous

Warnings

Cefotetan Contraindications
Condition
Risk Level
Notes
Anemia, Hemolytic
Do Not Combine
There are 20 known major drug interactions with Cefotetan.
Common Cefotetan Drug Interactions
Drug Name
Risk Level
Description
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Neomycin.
Tenofovir
Major
Cefotetan may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Cefotetan may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir disoproxil
Major
Cefotetan may increase the nephrotoxic activities of Tenofovir disoproxil.
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cefotetan.
image of a doctor in a lab doing drug, clinical research

Cefotetan Novel Uses: Which Conditions Have a Clinical Trial Featuring Cefotetan?

47 active trials are currently being conducted to investigate the potential of Cefotetan for Pre-Surgical Prophylaxis Therapy, Postoperative Infection Prophylaxis and Septic Management.
Condition
Clinical Trials
Trial Phases
Gonorrhea
0 Actively Recruiting
Urinary tract infection
0 Actively Recruiting
Pelvic Inflammatory Disease
0 Actively Recruiting
Osteomyelitis
0 Actively Recruiting
Antibiotics
0 Actively Recruiting
Bacteria
0 Actively Recruiting
Intraabdominal Infections
1 Actively Recruiting
Not Applicable
Communicable Diseases
0 Actively Recruiting
Postoperative Infections
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
surgical prophylaxis therapy
0 Actively Recruiting
prophylaxis of Postoperative Infections
0 Actively Recruiting

Cefotetan Reviews: What are patients saying about Cefotetan?

3.7Patient Review
3/17/2017
Cefotetan for Bacteroides Bacteria Infection of Female Pelvic Organs
Dizziness was a bit of an issue, but this medication was highly effective for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cefotetan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does cefotetan treat?

"Cefotetan injection is a cephalosporin antibiotic used to treat infections of the lungs, skin, bones, joints, stomach area, blood, female reproductive organs, and urinary tract. It is also used before surgery to prevent infections."

Answered by AI

What is the generic name for cefotetan?

"pneumoniae), Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia spp, Pseudomonas spp, Serratia spp.

Cefotan is indicated for the therapeutic treatment of infections of the urinary tract when caused by susceptible strains of designated organisms. These include infections caused by E. coli, Klebsiella spp (including K. pneumoniae), Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia spp, Pseudomonas spp, and Serratia spp."

Answered by AI

What type of antibiotic is cefotetan?

"Cefotetan is a cephalosporin antibiotic used to treat bacterial infections and to prevent infection during surgery."

Answered by AI

Is cefotetan a penicillin?

"Cefotetan is an antibiotic that is used to treat a variety of bacterial infections. It can also be used to help prevent infection before and during certain surgeries. This medication is a cephalosporin antibiotic."

Answered by AI

Clinical Trials for Cefotetan

Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Image of University of Missouri in Columbia, United States.

Antibiotics for Cat Bite Injuries

18+
All Sexes
Columbia, MO
Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand/forearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion/exclusion criteria. For inclusion, participants will be \>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and/or systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+/-2, day 14+/-2, and day 30+/-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand/forearm will be assessed for correlations with infections.
Phase 4
Recruiting
University of MissouriKevin M Klifto, DO, PharmD
Have you considered Cefotetan clinical trials? We made a collection of clinical trials featuring Cefotetan, we think they might fit your search criteria.Go to Trials
Image of UPMC-Presbyterian Hospital in Pittsburgh, United States.

Blue Light for Infections

18 - 65
All Sexes
Pittsburgh, PA
Our data suggest that modulating the characteristics of light carries the potential to modify the host response to injury and critical illness and thus, improve outcome. The ability to modify the host response to the stress of major operations and sepsis carries immense potential to improve patient care. The primary purpose of this study is to determine if exposure to bright blue (442nm) enriched light, by comparison to ambient white fluorescent light, reduces the inflammatory response or organ dysfunction in patients undergoing 1) medical treatment for pneumonia, 2) a 2-stage arthroplasty for surgical management of a septic joint, 3) surgery for a necrotizing soft tissue infection (NSTI), and 4) surgery for an intraabdominal infection (e.g., diverticulitis). We will expose participants to one of two (2) lighting conditions: 1) high illuminance (\~1700 lux,), blue (442nm) spectrum enriched light and 2) ambient white fluorescent light that provides the standard environmental lighting (\~300-400 lux, no predominant spectrum) of the hospital. Both cohorts will be exposed to a 12 hours:12 hours light:dark cycle photoperiod. Those subjects assigned to blue light will be asked to shine this small portable blue enriched light on themselves from 0800 to 2000 for 3 days. At the transition from light to dark, the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter. Thus, the total period of intervention is 72 hours. The outcome of interest is change in the inflammatory response after surgery for appendicitis or diverticulitis as measured by the following parameters: white blood cell count, heart rate, the development of abdominal abscess, serum cytokine concentrations. The outcome of interest is change in the inflammatory response during pneumonia as measured by the following parameters: white blood cell count, heart rate, and serum cytokine concentrations.
Recruiting
Has No Placebo
UPMC-Presbyterian Hospital (+2 Sites)Matthew R Rosengart, MD MPH
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security